Home › Companies › Gilead Sciences, Inc. › 2025-2026

Gilead Sciences, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Gilead Sciences, Inc.’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

33Reported items
1,400Asset managers
23,857Fund votes
2026-04-30Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Gilead Sciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Gilead Sciences, Inc.

These tallies are Gilead Sciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Gilead Sciences, Inc. — official shareholder meeting results, meeting held 2026-04-30
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jacqueline K. Barton, Ph.D.	1,013,176,696	21,056,724	938,657	--	95,008,389	Majority: yes
Elect Director: Jeffrey A. Bluestone, Ph.D.	1,017,337,149	16,873,041	961,887	--	95,008,389	Majority: yes
Elect Director: Sandra J. Horning, M.D.	1,002,426,858	31,078,619	1,666,600	--	95,008,389	Majority: yes
Elect Director: Kelly A. Kramer	995,947,854	38,240,224	983,999	--	95,008,389	Majority: yes
Elect Director: Ted W. Love, M.D.	1,016,607,688	17,592,385	972,004	--	95,008,389	Majority: yes
Elect Director: Harish Manwani	995,710,468	38,469,820	991,789	--	95,008,389	Majority: yes
Elect Director: Daniel P. O'Day	980,597,212	50,179,985	4,394,880	--	95,008,389	Majority: yes
Elect Director: Javier J. Rodriguez	1,019,197,783	15,002,200	972,094	--	95,008,389	Majority: yes
Elect Director: Anthony Welters	992,619,897	40,842,646	1,709,534	--	95,008,389	Majority: yes
Proposal 10	1,046,350,569	82,831,295	998,602	--	--	Majority: yes
The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:	954,325,805	77,503,947	3,342,325	--	95,008,389	Majority: yes
The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:	970,290,586	62,501,433	2,380,058	--	95,008,389	Majority: yes
The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:	280,044,780	752,716,225	2,411,072	--	95,008,389	Majority: no
The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:	134,042,210	886,986,584	14,143,283	--	95,008,389	Majority: no
The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:	7,262,421	1,022,330,186	5,579,470	--	95,008,389	Majority: no

Source: Gilead Sciences, Inc., Form 8-K — read the filing on EDGAR.

How asset managers voted at the Gilead Sciences, Inc. 2025-2026 meeting

Each item below shows how the 1,400 asset managers that disclosed a Gilead Sciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Gilead Sciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 29 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 954,325,805AGAINST: 77,503,947

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:”): 954,325,805 for, 77,503,947 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 77% for, 6% against (83% of the company cast a for/against vote).

The 1,358 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 94%

FOR: 94.4%AGAINST: 5.4%ABSTAIN: 0.1%NOT VOTED: 0.0%UNKNOWN: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy S” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	143,396,884	0	0	For
Vanguard	127,791,487	1,005	45	For
Capital Group	109,692,915	0	386	For
BlackRock	108,151,991	5,676	0	For
Invesco	80,075,342	40	2	For
Dodge & Cox	44,230,058	0	0	For
T. Rowe Price	41,931,599	12,003	0	For
State Street	38,059,236	429,258	0	For
GEODE CAPITAL MANAGEMENT, LLC	29,515,809	0	0	For
Capital Research Global Investors	28,581,373	0	0	For
JPMorgan	16,293,053	0	0	For
Charles Schwab	16,190,182	0	0	For
Wellington	12,642,207	0	0	For
Northern Trust	12,277,131	100,015	0	For
UBS	8,447,779	0	0	For
Nuveen	7,973,388	260	0	For
Goldman Sachs	7,119,467	0	0	For
American Century	6,931,903	0	0	For
TIAA	6,859,325	0	0	For
MELLON INVESTMENTS Corp	6,831,583	0	0	For
Legal & General Investment Management Ltd	130,711	6,140,978	0	Against
Amundi	0	6,203,061	0	Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	0	6,048,355	0	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	5,303,173	0	0	For
AllianceBernstein	5,284,231	0	0	For

Showing the 25 largest of 1,358 asset managers. See all 1,358 in the interactive database.

2. To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 8 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 970,290,586AGAINST: 62,501,433

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:”): 970,290,586 for, 62,501,433 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 78% for, 5% against (83% of the company cast a for/against vote).

The 249 asset managers below cast 99.0% of the shares they voted on this item FOR (501,188,776 for, 4,598,509 against).

FOR 99.0%

FOR: 501,188,776 (99.1%)AGAINST: 4,598,509 (0.9%)ABSTAIN: 126,949 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,763,639	652	32	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	386	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,499	208	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	0	3,393,694	0	Against
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 249 asset managers. See all 249 in the interactive database.

3. To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.

DIVERSITY, EQUITY, AND INCLUSION

Meeting held 2026-04-30.

Combines 5 wordings of this item as funds reported it.

0.1% fund support · no official result

AGAINST 99.7%

The 241 asset managers below cast 0.1% of the shares they voted on this item FOR (286,037 for, 502,878,984 against).

FOR: 286,037 (0.1%)AGAINST: 502,878,984 (99.8%)ABSTAIN: 919,280 (0.2%)UNKNOWN: 4,108 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metri” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	49	114,764,176	74	Against
Fidelity	0	78,590,115	0	Against
Capital Group	0	67,499,643	0	Against
BlackRock	0	49,241,726	0	Against
Invesco	0	38,663,991	0	Against
Dodge & Cox	0	19,998,392	0	Against
JPMorgan	0	15,929,448	0	Against
State Street	0	14,747,707	0	Against
T. Rowe Price	0	13,108,314	0	Against
Charles Schwab	0	7,852,508	0	Against
TIAA	0	6,806,803	0	Against
Hartford	0	4,760,332	0	Against
Columbia Threadneedle	0	4,563,061	0	Against
MFS	0	4,442,896	0	Against
American Century	0	3,393,694	0	Against
Pacer Funds Trust	0	3,288,510	0	Against
First Trust	0	3,056,858	0	Against
Jackson National	0	2,874,145	0	Against
Dimensional	0	2,697,114	0	Against
John Hancock	0	2,429,733	0	Against
WisdomTree	0	2,118,939	0	Against
INVESTMENT CO OF AMERICA	0	1,947,854	0	Against
ProShares	0	1,945,965	0	Against
Waddell & Reed	0	1,945,339	0	Against
MASTER INVESTMENT PORTFOLIO	0	1,914,333	0	Against

Showing the 25 largest of 241 asset managers. See all 241 in the interactive database.

4. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 10 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 1,013,176,696AGAINST: 21,056,724

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jacqueline K. Barton, Ph.D.”): 1,013,176,696 for, 21,056,724 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 82% for, 2% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,434,733 for, 269 against).

FOR 99.9%

FOR: 505,434,733 (100.0%)AGAINST: 269 (0.0%)ABSTAIN: 126,542 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,764,040	269	11	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

5. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 13 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 1,017,337,149AGAINST: 16,873,041

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jeffrey A. Bluestone, Ph.D.”): 1,017,337,149 for, 16,873,041 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 82% for, 1% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,434,788 for, 216 against).

FOR 99.9%

FOR: 505,434,788 (100.0%)AGAINST: 216 (0.0%)ABSTAIN: 126,542 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,764,095	216	11	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

6. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 13 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 1,002,426,858AGAINST: 31,078,619

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 1,002,426,858 for, 31,078,619 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 81% for, 3% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,390,665 for, 44,330 against).

FOR 99.9%

FOR: 505,390,665 (100.0%)AGAINST: 44,330 (0.0%)ABSTAIN: 126,553 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,763,923	379	22	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

7. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 995,947,854AGAINST: 38,240,224

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Kelly A. Kramer”): 995,947,854 for, 38,240,224 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 80% for, 3% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,344,242 for, 90,761 against).

FOR 99.9%

FOR: 505,344,242 (100.0%)AGAINST: 90,761 (0.0%)ABSTAIN: 126,543 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,763,840	470	12	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

8. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 13 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 1,016,607,688AGAINST: 17,592,385

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 1,016,607,688 for, 17,592,385 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 82% for, 1% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,434,805 for, 200 against).

FOR 99.9%

FOR: 505,434,805 (100.0%)AGAINST: 200 (0.0%)ABSTAIN: 126,542 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,764,112	200	11	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

9. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 995,710,468AGAINST: 38,469,820

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Harish Manwani”): 995,710,468 for, 38,469,820 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 80% for, 3% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.8% of the shares they voted on this item FOR (504,893,610 for, 541,395 against).

FOR 99.8%

FOR: 504,893,610 (99.9%)AGAINST: 541,395 (0.1%)ABSTAIN: 126,543 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,763,811	501	12	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

10. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 10 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 1,019,197,783AGAINST: 15,002,200

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Javier J. Rodriguez”): 1,019,197,783 for, 15,002,200 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 82% for, 1% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,444,814 for, 190 against).

FOR 99.9%

FOR: 505,444,814 (100.0%)AGAINST: 190 (0.0%)ABSTAIN: 126,542 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,764,121	190	11	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

11. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 992,619,897AGAINST: 40,842,646

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Anthony Welters”): 992,619,897 for, 40,842,646 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 80% for, 3% against (83% of the company cast a for/against vote).

The 240 asset managers below cast 99.9% of the shares they voted on this item FOR (505,369,620 for, 65,873 against).

FOR 99.9%

FOR: 505,369,620 (100.0%)AGAINST: 65,873 (0.0%)ABSTAIN: 126,553 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,763,764	536	22	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,707	0	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

12. To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-04-30.

Combines 10 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 980,597,212AGAINST: 50,179,985

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Daniel P. O'Day”): 980,597,212 for, 50,179,985 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 79% for, 4% against (83% of the company cast a for/against vote).

The 239 asset managers below cast 99.9% of the shares they voted on this item FOR (505,308,613 for, 129,286 against).

FOR 99.9%

FOR: 505,308,613 (99.9%)AGAINST: 129,286 (0.0%)ABSTAIN: 126,590 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,763,633	629	59	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,241,726	0	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,600	107	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,760,332	0	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,874,145	0	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 239 asset managers. See all 239 in the interactive database.

13. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATED

Meeting held 2026-04-30.

Combines 3 wordings of this item as funds reported it.

99.5% fund support · no official result

FOR 99.5%

The 233 asset managers below cast 99.5% of the shares they voted on this item FOR (501,603,866 for, 2,368,674 against).

FOR: 501,603,866 (99.5%)AGAINST: 2,368,674 (0.5%)ABSTAIN: 126,541 (0.0%)UNKNOWN: 4,006 (0.0%)NOT VOTED: 942 (0.0%)

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,652,852	111,460	10	For
Fidelity	78,590,115	0	0	For
Capital Group	67,499,643	0	0	For
BlackRock	49,234,588	7,138	0	For
Invesco	38,663,991	0	0	For
Dodge & Cox	19,998,392	0	0	For
JPMorgan	15,929,448	0	0	For
State Street	14,747,499	208	0	For
T. Rowe Price	13,108,314	0	0	For
Charles Schwab	7,852,508	0	0	For
TIAA	6,806,803	0	0	For
Hartford	4,759,326	1,006	0	For
Columbia Threadneedle	4,563,061	0	0	For
MFS	4,442,896	0	0	For
American Century	3,393,694	0	0	For
Pacer Funds Trust	3,288,510	0	0	For
First Trust	3,056,858	0	0	For
Jackson National	2,598,683	275,462	0	For
Dimensional	2,697,114	0	0	For
John Hancock	2,429,733	0	0	For
WisdomTree	2,118,939	0	0	For
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	1,945,965	0	0	For
Waddell & Reed	1,945,339	0	0	For
MASTER INVESTMENT PORTFOLIO	1,914,333	0	0	For

Showing the 25 largest of 233 asset managers. See all 233 in the interactive database.

14. To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.

OTHER SOCIAL ISSUES

Meeting held 2026-04-30.

Combines 3 wordings of this item as funds reported it.

0.8% fund support · no official result

AGAINST 99.0%

The 233 asset managers below cast 0.8% of the shares they voted on this item FOR (3,797,310 for, 499,331,346 against).

FOR: 3,797,310 (0.8%)AGAINST: 499,331,346 (99.1%)ABSTAIN: 981,102 (0.2%)NOT VOTED: 942 (0.0%)UNKNOWN: 102 (0.0%)

Largest asset managers voting on “To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patien” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	111,895	114,652,237	189	Against
Fidelity	0	78,590,115	0	Against
Capital Group	0	67,499,643	0	Against
BlackRock	29,619	49,212,107	0	Against
Invesco	0	38,663,991	0	Against
Dodge & Cox	0	19,998,392	0	Against
JPMorgan	0	15,929,448	0	Against
State Street	4,065	14,743,642	0	Against
T. Rowe Price	0	13,108,314	0	Against
Charles Schwab	0	7,852,508	0	Against
TIAA	0	6,806,803	0	Against
Hartford	1,006	4,759,326	0	Against
Columbia Threadneedle	0	4,563,061	0	Against
MFS	0	4,442,896	0	Against
American Century	0	3,393,694	0	Against
Pacer Funds Trust	0	3,288,510	0	Against
First Trust	0	3,056,858	0	Against
Jackson National	0	2,874,145	0	Against
Dimensional	0	2,697,114	0	Against
John Hancock	0	2,429,733	0	Against
WisdomTree	0	2,118,939	0	Against
INVESTMENT CO OF AMERICA	0	1,947,854	0	Against
ProShares	0	1,945,965	0	Against
Waddell & Reed	0	1,945,339	0	Against
MASTER INVESTMENT PORTFOLIO	0	1,914,333	0	Against

Showing the 25 largest of 233 asset managers. See all 233 in the interactive database.

15. To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.

CORPORATE GOVERNANCE

Meeting held 2026-04-30.

Combines 3 wordings of this item as funds reported it.

17% fund support · no official result

FOR 17%AGAINST 83%

The 232 asset managers below cast 17% of the shares they voted on this item FOR (85,054,544 for, 418,928,557 against).

FOR: 85,054,544 (16.9%)AGAINST: 418,928,557 (83.1%)ABSTAIN: 126,559 (0.0%)NOT VOTED: 942 (0.0%)UNKNOWN: 102 (0.0%)

Largest asset managers voting on “To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the A” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	114,057	114,650,238	28	Against
Fidelity	576,500	78,013,615	0	Against
Capital Group	67,499,643	0	0	For
BlackRock	36,172	49,205,554	0	Against
Invesco	0	38,663,991	0	Against
Dodge & Cox	0	19,998,392	0	Against
JPMorgan	0	15,929,448	0	Against
State Street	4,065	14,743,642	0	Against
T. Rowe Price	0	13,108,314	0	Against
Charles Schwab	2,112	7,850,397	0	Against
TIAA	0	6,806,803	0	Against
Hartford	1,006	4,759,326	0	Against
Columbia Threadneedle	4,563,061	0	0	For
MFS	0	4,442,896	0	Against
American Century	0	3,393,694	0	Against
Pacer Funds Trust	0	3,288,510	0	Against
First Trust	0	3,056,858	0	Against
Jackson National	0	2,874,145	0	Against
Dimensional	0	2,697,114	0	Against
John Hancock	1,843,756	585,977	0	For
WisdomTree	0	2,118,939	0	Against
INVESTMENT CO OF AMERICA	1,947,854	0	0	For
ProShares	0	1,945,965	0	Against
Waddell & Reed	0	1,945,339	0	Against
MASTER INVESTMENT PORTFOLIO	0	1,914,333	0	Against

Showing the 25 largest of 232 asset managers. See all 232 in the interactive database.

16. 14A Executive Compensation

AUDIT-RELATED

Meeting held 2026-04-30.

99.0% fund support · no official result

FOR 92%8%

The 13 asset managers below cast 99.0% of the shares they voted on this item FOR (28,674 for, 269 against).

FOR: 28,674 (91.6%)AGAINST: 269 (0.9%)ABSTAIN: 2,347 (7.5%)

Largest asset managers voting on “14A Executive Compensation” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Cove Private Wealth, LLC	14,140	0	0	For
REXFORD CAPITAL INC	5,062	0	0	For
NORTHERN LIGHTS FUND TRUST II	3,623	0	0	For
LEAVELL INVESTMENT MANAGEMENT, INC.	0	0	2,347	Abstain
COURIER CAPITAL LLC	1,928	0	0	For
McGowan Group Asset Management, Inc.	1,420	0	0	For
Blue Edge Capital, LLC	1,006	0	0	For
HARBOUR INVESTMENT MANAGEMENT LLC	710	0	0	For
Baker Avenue Asset Management, LP	372	0	0	For
OLD SECOND NATIONAL BANK OF AURORA	300	0	0	For
WOODARD & CO ASSET MANAGEMENT GROUP INC /ADV	0	269	0	Against
MQS Management LLC	83	0	0	For
Claret Asset Management Corp	30	0	0	For

17. Amend Omnibus Stock Plan

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-04-30.

94% Majority: yes · of votes cast

FOR 94%

FOR: 970,290,586AGAINST: 62,501,433

The 11 asset managers below cast 94% of the shares they voted on this item FOR (896,177 for, 55,212 against).

FOR 94%

FOR: 896,177 (94.2%)AGAINST: 55,212 (5.8%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Erste Asset Management GmbH	460,635	0	For
Empower	314,596	0	For
Lincoln Financial	5,764	49,905	Against
Advisors' Inner Circle Fund III	36,201	0	For
Vontobel Holding Ltd.	31,300	0	For
CLEARWATER INVESTMENT TRUST	18,461	0	For
NORTHERN LIGHTS FUND TRUST II	17,600	0	For
AGF Investments Trust	9,972	0	For
Maj Invest Holding A/S	0	5,307	Against
USCF ETF Trust	1,464	0	For
Canopy Partners, LLC	184	0	For

18. Report on Risks of Using ESG and DEI Metrics in Executive Compensation

COMPENSATIONMajority of the votes cast: no

Meeting held 2026-04-30.

0.8% Majority: no · of votes cast

AGAINST 99.2%

FOR: 7,262,421AGAINST: 1,022,330,186

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:”): 7,262,421 for, 1,022,330,186 against, per its Form 8-K (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 0.6% for, 82% against (83% of the company cast a for/against vote).

The 11 asset managers below cast 25% of the shares they voted on this item FOR (310,851 for, 916,108 against).

FOR 25%AGAINST 75%

FOR: 310,851 (25.3%)AGAINST: 916,108 (74.7%)

Largest asset managers voting on “Report on Risks of Using ESG and DEI Metrics in Executive Compensation” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Erste Asset Management GmbH	0	460,635	Against
Empower	0	314,596	Against
GuideStone	310,851	0	For
Lincoln Financial	0	55,669	Against
Advisors' Inner Circle Fund III	0	36,201	Against
CLEARWATER INVESTMENT TRUST	0	18,461	Against
NORTHERN LIGHTS FUND TRUST II	0	17,600	Against
AGF Investments Trust	0	9,972	Against
USCF ETF Trust	0	1,464	Against
CSM Advisors, LLC	0	1,445	Against
CIDEL ASSET MANAGEMENT INC	0	65	Against

19. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

Meeting held 2026-04-30.

100% fund support · no official result

FOR 100%

The 8 asset managers below cast 100% of the shares they voted on this item FOR (914,598 for, 0 against).

FOR: 914,598 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Vote
Erste Asset Management GmbH	460,635	For
Empower	314,596	For
Lincoln Financial	55,669	For
Advisors' Inner Circle Fund III	36,201	For
CLEARWATER INVESTMENT TRUST	18,461	For
NORTHERN LIGHTS FUND TRUST II	17,600	For
AGF Investments Trust	9,972	For
USCF ETF Trust	1,464	For

20. Report on Impact of Extended Patent Exclusivities on Patient Access

OTHER SOCIAL ISSUESMajority of the votes cast: no

Meeting held 2026-04-30.

13% Majority: no · of votes cast

13%AGAINST 87%

FOR: 134,042,210AGAINST: 886,986,584

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:”): 134,042,210 for, 886,986,584 against, per its Form 8-K (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 11% for, 71% against (82% of the company cast a for/against vote).

The 8 asset managers below cast 51.6% of the shares they voted on this item FOR (472,071 for, 442,527 against).

FOR 51.6%AGAINST 48.4%

FOR: 472,071 (51.6%)AGAINST: 442,527 (48.4%)

Largest asset managers voting on “Report on Impact of Extended Patent Exclusivities on Patient Access” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Erste Asset Management GmbH	460,635	0	For
Empower	0	314,596	Against
Lincoln Financial	0	55,669	Against
Advisors' Inner Circle Fund III	0	36,201	Against
CLEARWATER INVESTMENT TRUST	0	18,461	Against
NORTHERN LIGHTS FUND TRUST II	0	17,600	Against
AGF Investments Trust	9,972	0	For
USCF ETF Trust	1,464	0	For

21. Require Independent Board Chair

CORPORATE GOVERNANCEMajority of the votes cast: no

Meeting held 2026-04-30.

27% Majority: no · of votes cast

FOR 27%AGAINST 73%

FOR: 280,044,780AGAINST: 752,716,225

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:”): 280,044,780 for, 752,716,225 against, per its Form 8-K (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 23% for, 61% against (83% of the company cast a for/against vote).

The 8 asset managers below cast 53.5% of the shares they voted on this item FOR (489,671 for, 424,927 against).

FOR 53.5%AGAINST 46.5%

FOR: 489,671 (53.5%)AGAINST: 424,927 (46.5%)

Largest asset managers voting on “Require Independent Board Chair” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Erste Asset Management GmbH	460,635	0	For
Empower	0	314,596	Against
Lincoln Financial	0	55,669	Against
Advisors' Inner Circle Fund III	0	36,201	Against
CLEARWATER INVESTMENT TRUST	0	18,461	Against
NORTHERN LIGHTS FUND TRUST II	17,600	0	For
AGF Investments Trust	9,972	0	For
USCF ETF Trust	1,464	0	For

22. Ratify Appointment of Independent Auditors

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-04-30.

Combines 2 wordings of this item as funds reported it.

14% fund support · no official result

FOR 14%AGAINST 86%

The 7 asset managers below cast 14% of the shares they voted on this item FOR (77,452 for, 466,927 against).

FOR: 77,452 (14.2%)AGAINST: 466,927 (85.8%)

Largest asset managers voting on “Ratify Appointment of Independent Auditors” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Cardano Risk Management B.V.	0	466,927	Against
AMERICAN BEACON FUNDS	47,700	0	For
MARCO INVESTMENT MANAGEMENT LLC	17,341	0	For
Two Roads Shared Trust	6,658	0	For
NORTHERN LIGHTS FUND TRUST II	3,623	0	For
McGowan Group Asset Management, Inc.	1,420	0	For
HARBOUR INVESTMENT MANAGEMENT LLC	710	0	For

23. To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-05-07 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 929,612,739AGAINST: 89,351,501

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:”): 929,612,739 for, 89,351,501 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,242,000,000 outstanding shares: 75% for, 7% against (82% of the company cast a for/against vote).

The 7 asset managers below cast 93% of the shares they voted on this item FOR (623,737 for, 44,907 against).

FOR 93%

FOR: 623,737 (93.3%)AGAINST: 44,907 (6.7%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy S” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Investment Management Corp of Ontario	505,178	0	For
GLENMEDE FUND INC	72,407	0	For
OSSIAM	0	44,907	Against
Philip James Wealth Mangement, LLC	44,794	0	For
OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC	628	0	For
Slow Capital, Inc.	600	0	For
NORRIS PERNE & FRENCH LLP/MI	130	0	For

24. Adopt Incentive Stock Option Plan

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-04-30.

94% Majority: yes · of votes cast

FOR 94%

FOR: 970,290,586AGAINST: 62,501,433

The 5 asset managers below cast 89% of the shares they voted on this item FOR (19,893 for, 2,347 against).

FOR 89%11%

FOR: 19,893 (89.4%)AGAINST: 2,347 (10.6%)

Largest asset managers voting on “Adopt Incentive Stock Option Plan” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Cove Private Wealth, LLC	14,140	0	For
NORTHERN LIGHTS FUND TRUST II	3,623	0	For
LEAVELL INVESTMENT MANAGEMENT, INC.	0	2,347	Against
McGowan Group Asset Management, Inc.	1,420	0	For
HARBOUR INVESTMENT MANAGEMENT LLC	710	0	For

25. S/H Proposal - Corporate Governance

EXTRAORDINARY TRANSACTIONS

Meeting held 2026-04-30.

Combines 2 wordings of this item as funds reported it.

0% fund support · no official result

AGAINST 100%

The 4 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 7,464 against).

AGAINST: 7,464 (100.0%)

Largest asset managers voting on “S/H Proposal - Corporate Governance” at Gilead Sciences, Inc., 2025-2026
Asset manager	Against	Vote
NORTHERN LIGHTS FUND TRUST II	3,623	Against
HARBOUR INVESTMENT MANAGEMENT LLC	1,420	Against
McGowan Group Asset Management, Inc.	1,420	Against
Members Trust Co	1,001	Against

26. Say on Pay

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-04-30.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 954,325,805AGAINST: 77,503,947

The 4 asset managers below cast 10% of the shares they voted on this item FOR (13,649 for, 120,181 against).

10%AGAINST 90%

FOR: 13,649 (10.2%)AGAINST: 120,181 (89.8%)

Largest asset managers voting on “Say on Pay” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Genus Capital Management Inc.	0	120,181	Against
Arista Wealth Management, LLC	7,457	0	For
Empower	6,188	0	For
CHELSEA COUNSEL CO	4	0	For

27. Shareholder Proposal Regarding Report on Risks Associated with ESG and DEI Metrics in Executive Compensation

COMPENSATION

Meeting held 2026-04-30.

0% fund support · no official result

AGAINST 100%

The 4 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 1,595,808 against).

AGAINST: 1,595,808 (100.0%)

Largest asset managers voting on “Shareholder Proposal Regarding Report on Risks Associated with ESG and DEI Metrics in Executive Compensation” at Gilead Sciences, Inc., 2025-2026
Asset manager	Against	Vote
Union Investment Management GmbH	1,074,523	Against
Cardano Risk Management B.V.	466,927	Against
AMERICAN BEACON FUNDS	47,700	Against
Two Roads Shared Trust	6,658	Against

28. To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2026-03-06; no official results on file for that date.

4% fund support · no official result

AGAINST 96%

The 3 asset managers below cast 4% of the shares they voted on this item FOR (52,345 for, 1,433,679 against).

FOR: 52,345 (3.5%)AGAINST: 1,433,679 (96.5%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy S” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
SCHRODER INVESTMENT MANAGEMENT GROUP	0	1,433,679	Against
Robertson Stephens Wealth Management, LLC	47,368	0	For
GLOBALT Investments LLC / GA	4,977	0	For

29. Election of Directors (Majority Voting)

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-04-30.

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Vote
HARBOUR INVESTMENT MANAGEMENT LLC	6,390	For
NORTHERN LIGHTS FUND TRUST II	3,623	For
McGowan Group Asset Management, Inc.	1,420	For

30. S/H Proposal - Establish Independent Chairman

EXTRAORDINARY TRANSACTIONS

Meeting held 2026-04-30.

0% fund support · no official result

AGAINST 100%

The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 5,753 against).

AGAINST: 5,753 (100.0%)

Largest asset managers voting on “S/H Proposal - Establish Independent Chairman” at Gilead Sciences, Inc., 2025-2026
Asset manager	Against	Vote
NORTHERN LIGHTS FUND TRUST II	3,623	Against
McGowan Group Asset Management, Inc.	1,420	Against
HARBOUR INVESTMENT MANAGEMENT LLC	710	Against

31. Shareholder Proposal Regarding Independent Chair

CORPORATE GOVERNANCE

Meeting held 2026-04-30.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (521,285 for, 0 against).

FOR: 521,285 (100.0%)

Largest asset managers voting on “Shareholder Proposal Regarding Independent Chair” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Vote
Cardano Risk Management B.V.	466,927	For
AMERICAN BEACON FUNDS	47,700	For
Two Roads Shared Trust	6,658	For

32. Shareholder Proposal Regarding Report on Risk of Patent Exclusivities Delaying Patient Access

OTHER

Meeting held 2026-04-30.

90% fund support · no official result

FOR 90%10%

The 3 asset managers below cast 90% of the shares they voted on this item FOR (466,927 for, 54,358 against).

FOR: 466,927 (89.6%)AGAINST: 54,358 (10.4%)

Largest asset managers voting on “Shareholder Proposal Regarding Report on Risk of Patent Exclusivities Delaying Patient Access” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Cardano Risk Management B.V.	466,927	0	For
AMERICAN BEACON FUNDS	0	47,700	Against
Two Roads Shared Trust	0	6,658	Against

33. COMPENSATION

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-04-30.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,753 for, 0 against).

FOR: 1,753 (100.0%)

Largest asset managers voting on “COMPENSATION” at Gilead Sciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Members Trust Co	1,001	0	0	0	For
Capital Group	752	0	0	0	For

Largest Gilead Sciences, Inc. shareholders voting in 2025-2026

Ranked by the number of Gilead Sciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 1,242,000,000 shares outstanding at the time of that meeting.

Top Gilead Sciences, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	11.55%
2	Vanguard	10.29%
3	Capital Group	8.83%
4	BlackRock	8.71%
5	Invesco	6.45%
6	Dodge & Cox	3.56%
7	T. Rowe Price	3.38%
8	State Street	3.10%
9	GEODE CAPITAL MANAGEMENT, LLC	2.38%
10	Capital Research Global Investors	2.30%

Reported Gilead Sciences, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Gilead Sciences, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group	9.00%	DEF14A
BlackRock, Inc.	8.19%	DEF14A
FMR LLC	5.28%	13G
State Street	4.82%	13F
JPMorgan Chase	2.74%	13F
Gilead Sciences, Inc.	2.53%	13D
Geode Capital	2.39%	13F
T. Rowe Price	2.11%	13F
Morgan Stanley	1.89%	13F
Invesco	1.25%	13F

Percentages above are of 1,242,000,000 shares outstanding, as reported by Gilead Sciences, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Gilead Sciences, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Gilead Sciences, Inc.'s shareholder meeting held 2026-04-30, in the 2025-2026 proxy season, 1,400 asset managers reported how they voted in their SEC Form N-PX filings, covering 23,857 separate fund positions. Their filings are grouped here into 33 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our Named Executive Officers as presented… — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Gilead Sciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

Gilead Sciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).